



Jason Murata

Partner | San Francisco

Practice Areas

Intellectual Property

Contact

T: 415.490.1487

jmurata@axinn.com



[Download V-Card](#)

Jason Murata draws on over 20 years of experience to address clients' most critical intellectual property challenges. With a strong background in pre-trial, trial, and appellate litigation, he adeptly handles complex IP disputes across a wide range of industries, including pharmaceuticals, biopharmaceuticals, technology, consumer goods, and food products. His extensive litigation background also equips him to navigate critical issues relating to managing clients' IP risks and freedom to operate. *Law360* has recognized Jason as a "Legal Lion" for his skill in arguing before the Federal Circuit on behalf of his clients.

In addition to his active IP practice, Jason is a recognized leader in advancing workplace culture & opportunity within the IP community. Jason has also chaired the Intellectual Property Law Institute at the LGBTQ+ Bar Association's Lavender Law® Conference and Career Fair on multiple occasions and previously led the AIPLA IP Practice in Japan Committee.

In his pro bono practice, Jason has successfully represented prisoners in cases pertaining to violations of the U.S. Constitution's Equal Protection Clause.

Professional Activities

- National LGBTQ+ Bar Association, Judicial Nominations and Executive Appointments Committee (2024 – 2025)
- American Intellectual Property Law Association, Committee on IP Law Associations
- American Intellectual Property Law Association, Committee on Nominations (2024)
- American Intellectual Property Law Association, Committee on the Profession
- American Bar Association, Section of Intellectual Property Law

Experience

- *Mayne Pharma Int'l Pty Ltd. v. Merck & Co., Inc.*, No. 15-cv-00438 (D. Del.) (patent infringement action relating to Merck's Noxafil posaconazole products)
- *Globus Medical, Inc. v. DePuy Synthes Products, LLC*, No. 13-cv-00854 (D. Del.) (defend patent infringement action relating to spinal fusion implants)
- *Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc.*, Nos. 14-cv-03158-JBS-KMW & 14-cv-07252-JBS-KMW (D.N.J.) (obtained denial of motion for temporary restraining order in patent infringement action relating to generic aripiprazole drug product (Abilify))
- *Pfizer, Inc. v. Tiger Pharmaceuticals, LLC*, No. 14-cv-01501-AJT-TRJ (E.D. Va.); *Pfizer, Inc. v. Tiger Pharmaceuticals, LLC*, No. 14-cv-08958-GHW (S.D.N.Y.); *Johnson Matthey Inc. v. Pfizer, Inc.*, 2:15-cv-00014-AWA-TEM (E.D. Va.) (obtained dismissal of patent infringement action relating to dofetilide drug product within four months of filing of the action)
- *Depomed, Inc. v. Actavis Elizabeth LLC*, No. 3:12-cv-01358 (D.N.J.) and Appeal No. 14-1828 (Fed. Cir.) (bench trial in patent infringement action relating to generic once-daily gabapentin product)
- *The Procter & Gamble Co. v. Conopco, Inc.*, No. 13-CV-00732-TSB (S.D. Ohio) (represented Unilever in patent infringement action relating to antidandruff shampoo products)
- *Brandeis University v. Unilever United States, Inc.*, No. 12-cv-01510 (N.D. Ill.) (Posner, J.) (represented Unilever in patent infringement action brought by marketer of SmartBalance products relating to margarines and buttery spreads)
- *Hospira, Inc. v. Sun Pharmaceutical Industries, Inc.*, No. 2:10-cv-14514 (BAF/MJH) (E.D. Mich.) (defense of patent infringement action relating to generic dexmedetomidine drug product)
- *Tyco Healthcare Group LP, et al. v. Mutual Pharmaceutical Co., Inc., et al.*, Civil Action No. 07-cv-1299 (D.N.J.) and Appeal No. 2010-1513 (Fed. Cir.) (obtained summary judgment of invalidity that asserted patent was obvious, which was affirmed by Federal Circuit)

- *In re Gabapentin Patent Litigation*, MDL No. 1384, Master Civil Action No. 00-2931 (D.N.J.) (patent infringement dispute involving gabapentin)
- *Aventis Pharmaceuticals Inc., et al. v. Sun Pharma Global Inc., et al.*, Civil Action Nos. 09-cv-00325 & -05179; Civil Action No.: 2:09-cv-5179-JAG (D.N.J.) (patent infringement dispute involving fexofenadine and fexofenadine / pseudoephedrine products)
- *Roche Palo Alto LLC. v. Endo Pharmaceuticals Inc.*, Civil Action No. 10-cv-00261-GMS (D. Del.) (patent infringement dispute involving valganciclovir hydrochloride)
- *United States Gypsum Co. v. Lafarge North America, Inc., Lafarge S.A., et al.*, Civil Action No. 03-CV-6027 (N.D. Ill. 2003) (theft of confidential, proprietary and trade secret information and patent infringement involving gypsum drywall manufacturing)
- *Pall Corp. v. Entegris, Inc.*, Civil Action No. 07-CV-1869 (E.D.N.Y. 2007) (infringement dispute concerning filter media packing and capsule design)
- *Pall Corp. v. Entegris, Inc.*, Civil Action No. 05-CV-5894 (E.D.N.Y. 2005) (patent infringement dispute involving filter assembly methods and pre-wet packaging)
- *Entegris, Inc. v. Pall Corp.*, Appeal Nos. 2004-1440, 2005-1265, -1266, 2006-1374 (Fed. Cir. 2006) (appeal from preliminary injunction and contempt order in patent infringement dispute concerning filter assembly)
- *AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc.*, Appeal No. 04-1100 (Fed. Cir. 2004) (appeal in pharmaceutical case relating to generic extended-release felodipine tablets)
- *Ciba Specialty Chemicals Corp. v. Zinkan Enterprises Inc., et al.*, Civil Action No. C2 03 174 (S.D. Ohio 2002) (patent infringement dispute involving treatment of wastewater from coal mining)

Honors

- *Lawdragon*, 500 Leading Litigators in America (2025)
- *World Intellectual Property Review* Leaders (2024)
- *World Intellectual Property Review* Diversity Champion (2024)
- American Intellectual Property Law Association, Diversity Champion (2024)
- *Profiles in Diversity Journal* Diverse Lawyers Making a Difference Award Winner (2024)
- *Profiles in Diversity Journal* Asian Leadership Award Winner (2023)
- New Leaders in the Law – *Connecticut Law Tribune* (2014)

Education

- JD – Washington University School of Law (2002)

- MA, Biology – Washington University (2002)
- BS, Biochemistry – McMaster University (1999)

Admissions

- California
- Connecticut
- Illinois
- New York
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court Northern District of Illinois
- U.S. District Court Northern District of California

Quotes

“Their knowledge of the industry, law, and implications is deep and thoughtful. The quality of the work...is first-rate.”

— *Chambers USA*

“Their performance and service is outstanding. They are extremely responsive, give good explanations and keep you up to date.”

— *Chambers USA*